Skip to content
Screener

Celldex Therapeutics CLDX Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Rogers Corporation logo
Rogers CorporationROG
$17.7M-23.0%
Incyte logo
IncyteINCY
$25.56M-11.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$2.23M+89.2%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$983.41K+36.8%
TTR
Turn Therapeutics Inc.TTRX
$67.57K

Other financials

Income statement

See full
Revenue$22.0K-97.0%
Operating income-$80.6M-26.3%
Net income-$73.5M-29.9%
EPS (diluted)-$0.94-10.6%

Balance sheet

See full
Cash & equivalents$47.5M+106%
Total debt$4.9M+61.8%
Total equity$714.6M+9.0%
Total assets$782.3M+13.0%

Cash flow

See full
Operating cash flow-$57.4M-30.5%
CapEx$3.2M+337%
Free cash flow-$60.6M-35.4%

Valuation

See full
Market cap$3.26B+129%
Enterprise value$3.22B+129%
P/S20,646.4×+20,401×

Profitability

See full
Operating margin-206,220.3%-210,440pp
Net margin-190,220.9%-193,797pp
FCF margin-153,231%-156,630pp

Returns & leverage

See full
Return on equity-43.9%+70.0pp
Debt / equity0.0×
Current ratio11.8×-7.8×

Where this comes from

Reported directly by Celldex Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091984
Line itemJune 30, 2026December 31, 2025
Prepaid and other current assets7,11414,076
Total current assets724,931534,664
Property and equipment, net9,7565,334
Operating lease right-of-use assets, net5,0382,437
Intangible assets27,19027,190
Other assets15,43413,358
Total assets$782,349$582,983
Liabilities and stockholders’ equity

Item 1. Unaudited Financial Statements

FAQ

What is Celldex Therapeutics's operating lease ROU assets?
Celldex Therapeutics (CLDX) reported operating lease ROU assets of $5.04M in Q2 2026.
How has Celldex Therapeutics's operating lease ROU assets changed year-over-year?
Celldex Therapeutics's operating lease ROU assets increased by 61.4% year-over-year, from $3.12M to $5.04M.
What is the long-term trend for Celldex Therapeutics's operating lease ROU assets?
Over 5 years (2020 to 2025), Celldex Therapeutics's operating lease ROU assets has grown at a -6.7% compound annual growth rate (CAGR), from $3.45M to $2.44M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Celldex Therapeutics's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude